直接抗病毒药物治疗丙型肝炎病毒感染与 incident 肝癌风险:一项回顾性队列研究
这项美国行政索赔数据的回顾性队列研究纳入30183例暴露于直接抗病毒药物(DAA)的成人丙型肝炎病毒(HCV)患者,并与137502例未治疗和12948例干扰素治疗的对照比较。调整后,DAA治疗与肝癌风险显著低于未治疗(调整HR=0.84,95%CI:0.73-0.96)及低于DAA前时代干扰素治疗(HR=0.69,95%CI:0.59-0.81)相关。
要点
- DAA治疗者较未治疗者年龄更大、男性更多、基线肝硬化更多。
- 调整后DAA治疗与肝癌风险较未治疗显著降低相关(调整HR=0.84,95%CI:0.73-0.96)。
- DAA治疗与肝癌风险较DAA前时代干扰素治疗显著降低相关(HR=0.69,95%CI:0.59-0.81)。
核心结论
- 在这项大型人群研究中,DAA为基础的治疗与肝癌风险较未治疗HCV患者及较DAA前时代干扰素治疗均降低相关。
- 作者预期随着DAA治疗者随访时间累积,DAA治疗的长期获益将更明显。
研究设计与样本
- 回顾性队列研究,使用截至2017年3月31日的美国行政索赔数据。
- 纳入30183例暴露于DAA的成人HCV患者、137502例同期无HCV治疗证据的成人HCV患者和12948例DAA引入前接受干扰素治疗的HCV患者。
- 纳入患者至少12个月 prior 入组且基线无肝癌证据。
- 采用Cox比例风险方法计算肝癌风险的风险比(HR)。
主要发现
- 与未治疗HCV患者相比,DAA治疗患者年龄更大、男性比例更高、基线肝硬化比例更高。
- 调整后,DAA治疗与肝癌风险较未治疗显著降低相关(调整HR=0.84,95%CI:0.73-0.96)。
- DAA治疗与肝癌风险较DAA前时代干扰素治疗显著降低相关(HR=0.69,95%CI:0.59-0.81)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Eradication of hepatitis C virus (HCV) infection via interferon-based treatment lowers hepatocellular carcinoma risk; some research suggests this effect extends to interferon-free treatment. AIMS: The objective of this retrospective cohort study was to examine the association of direct-acting antiviral (DAA) exposure with risk of incident liver cancer in real-world data. METHODS: From United States administrative claims data through March 31, 2017, we identified 30 183 adult HCV patients exposed to DAAs. For comparison, we identified contemporary adult HCV patients without evidence of HCV treatment (N = 137 502), and historical HCV patients treated with interferon prior to the introduction of DAAs (N = 12 948). Included patients had at least 12 months of prior enrolment and no evidence of prior liver cancer at baseline. Hazard ratios (HRs) estimating risk of incident liver cancer associated with DAA treatment were calculated using Cox proportional hazards methods. RESULTS: Relative to untreated HCV patients, DAA-treated patients were older, more likely to be male, and more likely to have cirrhosis at baseline. After adjustment, DAA treatment was associated with a significantly reduced risk of liver cancer relative to no treatment (adjusted HR = 0.84, 95% CI: 0.73-0.96), and relative to interferon-based treatment in the pre-DAA era (HR = 0.69, 95% CI: 0.59-0.81). CONCLUSIONS: In this large, population-based study, DAA-based treatment was associated with a reduced risk of incident liver cancer relative to both no HCV treatment and to interferon-based treatment in the pre-DAA era. As additional follow-up time of DAA-treated patients accrues, we anticipate that the long-term benefits of DAA treatment will become more apparent.
引用
- Singer AW, Reddy KR, Telep LE, et al. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther. 2018. PMID: 29516535. doi:10.1111/apt.14593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。